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Background: Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a
framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories
and cost distributions into account.
Methods: Swiss mandatory health insurance claims from 1840 persons with hospitalization for MI in 2014 were
analysed. Included persons were predominantly male (74%), had a median age of 73 years, and 71% were pre-
exposed to drugs for secondary prophylaxis, prior to index hospitalization. Guideline compliance was defined as
being prescribed recommended 4-class drug prophylaxis including drugs from the following four classes: beta-
blockers, statins, aspirin or P2Y12 inhibitors, and angiotension-converting enzyme inhibitors or angiotensin receptor
blockers. Health care expenditures (HCE) accrued over 1 year after index hospitalization were compared by
compliance status using two-part regression, trajectory analysis, and counterfactual decomposition analysis.
Results: Only 32% of persons received recommended 4-class prophylaxis. Compliant persons had lower HCE (−
4865 Swiss Francs [95% confidence interval − 8027; − 1703]) and were more likely to belong to the most favorable
HCE trajectory (with 6245 Swiss Francs average annual HCE and comprising 78% of all studied persons).
Distributional analyses showed that compliance-associated HCE reductions were more pronounced among persons
with HCE above the median.
Conclusions: Compliance with recommended prophylaxis was robustly associated with lower HCE and more
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Background
Unwarranted variation in health care provision, reflected
by deviation from treatment recommendations, is an
ubiquitous problem and is associated with inefficient re-
source allocation, suboptimal treatment outcomes, lower
quality of care, and higher health care expenditures
(HCE) [1, 2]. However, to identify which health care ser-
vices are ineffective or appropriate for a specific patient
is challenging.
A crucial step towards improving efficiency of care is
to establish a link between deviations from recom-
mended care and inferior health and financial outcomes.
Real-world studies of care provision are usually retro-
spective, observational, and relying on secondary data
sources (that is, data initially collected for other pur-
poses), which brings about risks of biases such as re-
sidual confounding [3]. Among the potential biases
described in the literature the “healthy adherer bias” is
of particular concern [4]. This bias circumscribes the
effect that healthier persons tend to adhere better to
prescribed treatments, for example because they are gen-
erally more health-conscious. Therefore, compliance
may appear to exert beneficial effects on specific health
outcomes when such benefits are driven by unmeasured
comparator group differences.
Compliance has different facets: It can involve 1) pre-
scription compliance of physicians with recommended
guidelines, or 2) drug refill, or 3) intake by patients.
Moreover, health care needs, as well as treatment com-
pliance are often incompletely captured by routine data-
bases (e.g. health insurance claims) because persons not
accessing care are not recorded and standardized diag-
nostic information is often missing. Neither are actual
drug intake by patients commonly part of administrative
or health claims databases. Additionally, there is cur-
rently no established methodological framework for in-
vestigations into HCE implications of (non-)compliance
with recommended health care. The limited scientific lit-
erature on the topic is dominated by mean-based
methods, that is, cost outcomes are aggregated to total
cost averages and analyzed in regression frameworks.
While certainly valid and appropriate under clearly de-
fined circumstances (e.g. cost-effectiveness studies
nested in randomized trials), such approaches tend to
discard valuable information regarding cost distribution,
timing of clinical events, or the existence of subgroups
“falling outside the norm”. Specifically, treatment recom-
mendation compliance may not translate into health and
cost benefits over the full disease-severity spectrum, but
be limited to specific subgroups such as healthier per-
sons without co-morbidities.
Therefore, this study aimed to revisit the effect of pre-
scription and prescription fill compliance (as covered by
health insurance claims databases) on different monetary
and health outcomes, using the well-described example
of secondary prevention of myocardial infarction (MI).
Pharmacological prevention after acute MI events is, in
most circumstances, considered standard of care by
major treatment recommendations [5–8]. Treatment
recommendations state that prophylactic treatment
should be initiated after hospital discharge, ideally in-
cluding drugs from 4 classes. In particular, prophylactic
treatment should contain dual antiplatelet therapy
(DAPT) including aspirin and a P2Y12 inhibitor (prasu-
grel, ticagrelor, or clopidogrel), lipid-lowering drugs,
particularly high-intensity statins (STAT), angiotension-
converting enzyme (ACE) inhibitors or angiotensin re-
ceptor blockers (ARB), and beta-blockers (BB). However,
real-world observations suggest that patients are fre-
quently also prescribed treatment combinations with less
than four drug classes (e.g. 3-class treatments based on
STAT, ACE inhibitors/ARB, and BB) [5, 9].
The efficacy of these treatment combinations - in
terms of prevention of further MIs, mortality, or MI-
caused re-hospitalizations - has been demonstrated by
randomized controlled trials. However, the real-life ef-
fectiveness, particularly in light of expectable imperfect
compliance by physicians (in timely prescribing these
drugs) and patients (by not taking all recommended
drugs), as well as financial outcomes of taking sec-
ondary prevention, are much less explored [10].
Several studies have reported substantial net cost ben-
efits (that is, overall reduced health care expenditures)
among persons who complied with recommendations
compared with non-compliers, despite compliers
having accrued higher medication expenditures [3,
11–13]. Moreover, secondary prophylaxis has been as-
sociated with clinical benefits [9, 14, 15].
On the basis of health insurance claims data of per-
sons who were hospitalized for an MI event, this study
evaluated health and financial outcome differences
between persons who were prescribed (and have filled
prescriptions for) secondary prevention of MI as recom-
mended by guidelines compared to others who were not.
The database did not allow to determine, however,
whether drugs were truly taken in by patients. Standard
analyses were complemented by novel methods that
cover additional outcome dimensions by looking at dis-
tributional cost differences and cost trajectory differ-
ences between compliance groups, thereby leading to




This study evaluated the HCE implications of non-
compliance to MI secondary prevention by applying re-
cent methods from the causal inference framework to
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better control for healthy adherer bias (Fig. 1, analysis
1). HCE distributions (Fig. 1, analysis 2) and longitudinal
perspectives (Fig. 1, analysis 3) were applied to provide a
more comprehensive picture of (economic) conse-
quences of compliance and to facilitate the investigation
of subgroup-specific effects [16].
Setting and location
All analyses were performed using health insurance
claims data. Swiss mandatory health insurance charac-
teristics are described elsewhere [17]. In brief, the
insurance is comprehensive and reimburses costs
using fixed fee (inpatient) and fee-for-service (out-
patient) systems. There is a standard annual deduct-
ible of CHF 300 (that is, the insurance only covers
HCE exceeding the deductible amount). Insurees can
receive premium rebates for choosing higher deduct-
ibles (CHF 500 to 2500). Of note, the high deduct-
ibles and out-of-pocket payments of the Swiss system
have been criticized for leading to foregone healthcare
by some studies [18].
Study population
The analysis is based on anonymized, administrative
claims data from mandatory health insurance, provided
by Helsana Insurance Group. This health insurer covers
approximately 1.2 million people (15% of the full popu-
lation), representative for the Swiss population. The
database also included information on enrollees’ socio-
demographic characteristics (including date of death),
choice of insurance characteristics, as well as details on
all reimbursed medical services (e.g. date of care
provision, length of stay).
As illustrated in Fig. 2, this analysis included persons
who were insured with Helsana during 2014 and 2015.
Persons were selected if they were hospitalized with an
MI (index hospitalization) until Dec. 27, 2014, as indi-
cated by the International Disease Classification Version
10 (ICD-10) codes I21 (acute MI) and I22 (subsequent
MI). We excluded patients with incomplete insurance
coverage in 2014, asylum seekers, patients living outside
Switzerland, Helsana employees, patients living in nurs-
ing homes and receiving lump-sum reimbursement
(which could mask some services received), and those
Fig. 1 Study Flow Chart. Prior exposure was defined as having received P2Y12 inhibitors, ACE/ARB (angiotensin converting enzyme inhibitors/
angiotensin-receptor blockers), Aspirin, or Beta blocker prior to Index date. Abbreviations: MI: Myocardial Infarction
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not surviving until the end of the assessment period
(Fig. 2) [18].
Study perspective and time horizon
This study analysed cost consequences from the view
point of a Swiss health insurer. That is, only costs were
considered that were reimbursable to insurees by
mandatory health insurance. The cost contributions of
Swiss cantons for inpatient stays (55% of inpatient costs)
were not considered because they are handled directly
between cantons and insurers and are therefore largely
unaffected by insurance-scheme induced (dis-)incentives
for compliance.
Currency, price date, and conversion
All HCE are expressed in Swiss Francs (CHF), with 1
CHF being the equivalent of 0.92 Euros or 1 US $ (as of
October 2019). Because all outcome analyses encompass
a 360-day time-frame, no discount rates were applied.
Ethics
Study data were anonymized before analysis. According
to the national regulations, ethical approval was not re-
quired for this type of study.
Outcome and explanatory variables
Economic outcome variables
This study analyzed HCE accrued during the outcome
observation period (Fig. 2) from days 31 to 390 after dis-
charge from the index hospitalization, considering all in-
patient and outpatient services received during that
period. HCE was categorized into outpatient treatment
expenditures, inpatient care, drugs, and other costs (such
as aids, home care). The primary outcome of the ana-
lyses was total HCE, but secondary analyses also looked
into specific HCE categories (especially drug costs).
Health outcome variables
In addition, selected health outcomes were analyzed sep-
arately, namely deaths or hospitalizations occurring until
360 days during the outcome observation period (Fig. 2).
Main explanatory variable: compliance
The main explanatory variables were compliance to the
recommended treatment, defined by reimbursement
claims recorded within 30 days after the index date. The
30-day cut-off was chosen based on the reasoning that
this time frame provided ample time for re-filling a pre-
scription (as patients sometimes receive medications for
a few days at hospital discharge).
Treatment recommendation compliance was defined
as having filled one or more prescriptions for a 4-class
combination therapy including STAT, BBs, ACE, and ei-
ther aspirin or P2Y12 inhibitors. In sensitivity analyses,
persons who received combination therapy containing at
least 3 out of the 4 classes were also considered to be
treatment recommendation compliant.
Other explanatory variables
All analyses considered socio-demographic, morbidity-,
and insurance-related factors. Included variables com-
prised age, sex, living in a French- or Italian-speaking (as
opposed to German-speaking) canton, urbanity of place
of living (categorized as rural, sub-urban, or urban), hav-
ing a high annual deductible of >CHF 500, having at
least one supplementary health insurance, being in a
managed care model, having pre-existing chronic mor-
bidities requiring regular medication intake (as identified
by pharmaceutical cost groups), having used anticoagu-
lation drugs (heparin, vitamin K antagonists, athrombin
[19]), having had inpatient stays of at least 3 days or high
medication expenditures of at least CHF 5000 in the
year prior to the baseline hospitalization. Pharmaceutical
cost groups (PCG) are a widely employed means to reli-
ably derive the presence of certain co-morbidities on the
Fig. 2 Study design and definitions of timelines. Abbreviations: MI: myocardial infarction; d: days
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basis of prescriptions of disease-specific drugs (e.g.
against HIV) [20].
Furthermore, any use of medications used for MI pre-
vention before the index hospitalization (screening
period, Fig. 2) was recorded. Study subjects were classi-
fied by pre-exposure based on prior use of the drugs,
such as P2Y12 inhibitor, ACE, ARB, BB, but not high-
intensity statins because these are frequently prescribed
without a direct link to an elevated MI risk.
Because the majority of included patients (71%) were
pre-exposed to MI prevention drugs (potentially indicat-
ing that the index hospitalization was not the first car-
diovascular event), all analyses were performed on the
full sample (n = 1840) and on a subset of patients with-
out pre-exposure (n = 542).
Statistical analysis
Three analyses were conducted to investigate different
dimensions of cost differences (Fig. 1). Analysis 1 applied
two-part models to annual HCE and medication-related
HCE, to identify differences between the groups of com-
pliers and non-compliers. Separate models were esti-
mated for the two compliance definitions (4-class
treatments and at least 3-class treatments in the main
and sensitivity analysis, respectively). The choice of sen-
sitivity analysis was motivated by a preliminary analysis
of different exposure categories that indicated high num-
bers of 3-class combination prescriptions (Table 1).
Two-part models consisted of a logit-part that models
the probability of having non-zero HCE, based on covar-
iates x for individual i [21, 22]. The second part included
a generalized linear model that estimates the distribution
of non-zero HCE.
HCEið j xiÞ ¼ Pr HCEi > 0ð j xiÞ  Pr HCEið jHCEi > 0; xiÞ
After initial explorations, a gamma distribution and
log-link was chosen for this analysis [21]. The two-part
regression estimates were then back-transformed into
Swiss Francs [23].
Initial analyses led us to speculate that some persons
may not receive prophylactic medications as recom-
mended due to reasons that also influence the outcome
of interest (“healthy adherer bias”). Moreover, a non-
negligible number of persons died during the observa-
tion period. To mitigate these potential problems,
inverse probability weighted models were estimated [24].
Weights were derived from a multivariable logistic
regression on having drug reimbursement claims that
indicate compliance with 4-class treatments (or 3- and
4-class treatments in sensitivity analysis) within 30 days
of the index date as well as a separate multivariable re-
gression model for having died after the end of the as-
sessment period and before or at end of the observation
period. Death during the observation period may have
affected our analysis of cumulative HCE in two ways: 1)
deceased persons contributed less observation months to
the analysis, and 2) end-of-life costs tend to be dispro-
portionally high. Therefore, imbalances in death rates
across treatment compliance arms may translate into
biased estimates of HCE differences between compliance
groups.
To mitigate these biases, person-specific weights were
calculated as the inverse of the model-based predicted
probabilities for receiving recommended drugs and for
having died (whereby predictions from both regression
models were multiplied to create a single weight). These
combined weights were then applied to the two-part re-
gression analysis.
We hypothesized that non-compliance will lead to sta-
tistically significantly higher HCE after adjustments for
group differences, healthy adherer bias and censoring due
to death during the observation period (Hypothesis 1).
Analysis step 2 addressed the issue of compliance ef-
fects possibly not being equal across the full HCE distri-
bution (e.g. with an effect only visible in high-cost
groups). Therefore, we applied a method for counterfac-
tual decomposition to explore differences between the
groups of compliant and non-compliant persons across
the full HCE distribution [25]. This was achieved by esti-
mating the quantile function of compliant and non-
compliant persons across HCE distribution deciles (with
9 split points) and by adjusting for pre-specified
covariates. HCE differences between compliant and non-
compliant persons were then estimated per quantile,
adjusted for population differences between the two
groups [25]. Statistical significance was assessed by
bootstrap-generated 95% confidence intervals.
We hypothesized that HCE differences between com-
pliant and non-compliant persons are not homogenous
across the full cost spectrum (Hypothesis 2).
In addition, analysis 3 compared longitudinal age- and
sex-adjusted HCE trajectories between compliant and
non-compliant groups, thereby only considering patients
who survived the full observation period because the
method does not allow for censoring [26]. Individual
HCE trajectories of monthly aggregated, age- and sex-
adjusted HCE were smoothed using fifth-degree polyno-
mial linear regression and then k-means clustered, which
produced a trajectory-based classification. The optimal
number of trajectory groups was determined by an algo-
rithm assessing explained variance and classification sta-
bility (supplementary Figure 1).
We hypothesized that the trajectory analysis would
yield groups that are associated with unfavorable HCE
profiles (e.g. high overall costs, substantial spikes) and
that non-compliant groups would tend to congregate
more in such high-cost groups (Hypothesis 3).
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Hypothesis 3 was specifically tested using multinomial
logistic regressions, with trajectory groups treated as
outcome variables, compliance status (yes/no) as vari-




As illustrated by Fig. 1, 1,840 patients had a
hospitalization due to an MI and were discharged alive.
Of these, 1298 (70.5%) had pre-exposure to secondary
prevention drugs, possibly suggesting that the index
hospitalization did not represent their first cardiovascu-
lar event. Overall, 175 of 1840 (9.5%) persons died dur-
ing the outcome observation period.
Table 1 illustrates further baseline characteristics,
stratified by pre-exposure status. Of note, persons with
pre-exposure were markedly older (median of 76 years
compared to 61 years in the unexposed group), more fre-
quently female (n = 497, 38% vs. n = 157, 29%), and had
more pre-existing, medication-treated hypertension (n =
661, 51% vs. n = 48, 9%) and type 2 diabetes (n = 343,
Table 1 Baseline Characteristics




N 1840 (100%) 542 (100%) 1298 (100%)
Demographics
Median age [interquartile range] 73.0 [61.5; 82.0] 61.0 [53.0; 73.0] 76.0 [67.0; 84.0]
Female sex 654 (35.5%) 157 (29.0%) 497 (38.3%)
Living in French/Italian speaking cantons (vs. Swiss German) 466 (25.3%) 136 (25.1%) 330 (25.4%)
Living in urban region (vs. rural/suburban) 1391 (75.6%) 413 (76.2%) 978 (75.3%)
Insurance Characteristics
Annual deductible > 500 Swiss Francs 240 (13.0%) 147 (27.1%) 93 (7.2%)
Having supplementary insurance 1408 (76.5%) 398 (73.4%) 1010 (77.8%)
Having a managed care contract 741 (40.3%) 253 (46.7%) 488 (37.6%)
Prior medication use for chronic co-morbidities
Cancer 33 (1.8%) 7 (1.3%) 26 (2.0%)
Cardiovascular diseases 1361 (74.0%) 63 (11.6%) 1298 (100.0%)
Type 1 or type 2 diabetes 382 (20.8%) 39 (7.2%) 343 (26.4%)
Hypertension 709 (38.5%) 48 (8.9%) 661 (50.9%)
Median number of chronic comorbidities [interquartile range] 3.0 [2.0; 3.0] 3.0 [2.0; 3.0] 3.0 [3.0; 3.0]
High-intensity statin use prior index date 694 (37.7%) 45 (8.3%) 649 (50.0%)
Inpatient stays prior to index date 428 (23.3%) 50 (9.2%) 378 (29.1%)
High outpatient medication costs prior to index date 154 (8.4%) 24 (4.4%) 130 (10.0%)
Treatments received within 30 days after index date
Aspirin 1212 (65.9%) 455 (83.9%) 757 (58.3%)
P2Y12 inhibitors 1191 (64.7%) 406 (74.9%) 785 (60.5%)
ACE/ARB 1144 (62.2%) 366 (67.5%) 778 (59.9%)
Betablocker 1117 (60.7%) 358 (66.1%) 759 (58.5%)
High-intensity statins 990 (53.8%) 386 (71.2%) 604 (46.5%)
Combination treatments received
Three drug classesa 486 (26.4%) 161 (29.7%) 325 (25.0%)
Four drug classesa 595 (32.3%) 236 (43.5%) 359 (27.7%)
Clinical outcomes 390 days after index date (30 day assessment period and 360 day outcome observation period)
Having died after index date 175 (9.5%) 24 (4.4%) 151 (11.6%)
Having had inpatient hospital stays after index date 735 (39.9%) 146 (26.9%) 589 (45.4%)
a Four class treatments include high intensity statins, beta-blockers, ACE/ARB and either Aspirin or P2Y12 inhibitors. Three class treatments only include three of
the four drug classes
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26% vs. n = 39, 7%). Table 1 further shows data on com-
pliance status, which – globally – varied from 54 to 66%
for individual drugs. Uptake of 4- and 3-class combin-
ation prophylaxes was calculated at 32% (n = 595) and
27% (n = 486) of all patients, respectively.
Median [interquartile range] HCE for the observation
period were CHF 6779 [2329; 18,390] for the full popu-
lation, of which a median of CHF 1633 [778; 3028] for
medication expenditures. In the subpopulation of previ-
ously unexposed persons, corresponding figures for HCE
and medication costs were CHF 3455 [1638; 9631] and
CHF 1058 [593; 1942], respectively.
Description of health outcomes during outcome
observation period
When grouping the full sample (n = 1840, including pa-
tients with pre-exposure) by compliance with 4-class
combination therapy (3- or 4-class therapy in the sensi-
tivity analysis, respectively), the number and percentage
of persons dying during the outcome observation period
was n = 154, 12% (n = 121, 16%) in the group of non-
compliers (supplementary Table 1). By contrast, only
n = 21, 3.5% (n = 54, 5%) of compliers died during the
outcome observation period. Multivariable odds ratios
from logistic regression also indicated a nearly 50%
lower mortality among compliant persons (odds ratio in
main analysis 0.52 [95% confidence interval 0.30; 0.91];
sensitivity analysis 0.64 [0.44; 0.92], supplementary
Table 1).
Furthermore, the risk for re-hospitalization during the
observation period was similar between compliers (main
analysis: n = 217, 36.5%; sensitivity analysis: n = 397,
36.7%) and non-compliers (n = 518, 41.6% and n = 338,
44.5%, respectively, supplementary Table 1).
Mean-based comparisons
Unadjusted total HCE differences for compliant and
non-compliant persons are shown in Table 2, stratified
by pre-exposure status to prophylactic drugs. Crude
average HCE were CHF -5260 lower in persons receiving
4-class treatment. Moreover, the table presents results
from standard two-part and inverse probability weighted
models. In the main analysis, persons receiving 4-class
combination treatment had overall HCE that were CHF




3- & 4-class combination
(sensitivity analysis)













Crude difference, mean [95%CI] −5260 [− 7890; − 2630] − 5142 [− 7640; − 2644]
TwoPM, unweighted
Predicted difference [95%CI]
−2144 [− 4956; 668] − 2737 [− 6081; 606]
TwoPM, IPTW
Predicted difference [95%CI]
−4865 [−8027; −1703] − 3837 [− 8703; 1030]













Crude difference, mean [95%CI] −2935 [− 7466; − 1596] − 5347 [−10,410; − 285]
TwoPM, unweighted
Predicted difference [95%CI]
−1708 [− 4688; 1273] − 4389 [− 10,158; 1380]
TwoPM, IPTW
Predicted difference [95%CI]
−4048 [− 8727; 632] − 6974 [− 17,959; 4011]
HCE amounts represent Swiss francs (CHF).Two-part models were estimated for compliance status to a 4- or 3- and 4- class combination treatment (main variable
of interest shown in the table) and adjusted for age, sex, having a high deductible, participating in a managed care model, having at least one supplementary
insurance, living in a French-speaking or Italian-speaking canton, degree of urbanity of place of living, having had high medication expenditures of at least CHF 5′
000 within 360 days before the index date, having had an inpatient hospital stay within 360 days before the index date (other than the index hospitalization for
myocardial infarction), as well as the presence of pharmaceutical cost groups (co-morbidites) as confounders (coefficients not shown)
In addition, inverse probability for compliance to a specific drug combination (IPTW) was applied to further adjust for the “healthy adherer bias”. Inverse
probability weights were estimated by means of a multivariable logistic regression with compliance with a specific drug (as indicated by the column heading) as
outcome variable and the same variables as for the two-part model potential predictors
Abbreviations: HCE health care expenditures, TwoPM Two-part model, IPTW Inverse probability of treatment weights, IQR Interquartile Range, 95% CI 95%
Confidence Intervals. Estimates with CI not including 0 are in bold
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-2144 lower compared to non-compliant persons in the
unweighted, basic model. When applying inverse prob-
ability weights derived from multivariable logistic regres-
sion (supplementary Table 2), this difference increased
to CHF -4865 and reached statistical significance, but
was still smaller than the crude average difference. Esti-
mated differences were somewhat lower when only ana-
lyzing persons without pre-exposure, with a crude
average difference of CHF -2935, CHF -1708 in the un-
weighted and CHF -4048 in the weighted model, and did
not reach statistical significance. HCE differences were
nominally of similar (full population) or even larger (un-
exposed population) magnitude when considering the
use of 3- or 4-class combination treatments as compliant
(sensitivity analysis), but also did not reach statistical sig-
nificance (Table 2).
Moreover, medication costs did not differ statistically
significantly between compliance groups, but were nom-
inally higher for compliers in the subgroup of persons
without prior pre-exposure to prophylactic drugs (sup-
plementary Table 3).
Counterfactual distributional differences
The results from the distributional analyses are pre-
sented in Fig. 3 and Table 3. Unadjusted distributions of
HCE are displayed as split points for the HCE deciles in
the second column of Table 3. For example, in the full
population, the HCE deciles ranged from CHF 55 in the
lowest to CHF 42,046 for the highest decile.
The counterfactual decomposition analysis was used
to investigate HCE differences between compliance
groups over the full HCE distribution (stratified by dec-
iles), taking into account important confounders. In the
main analysis, compliance-linked HCE differences were
non-zero (indicating lower costs in compliant persons)
and reached statistical significance from the fifth decile
upward in the distribution (ranging from CHF 995 in
the fifth to CHF 3516 in the ninth decile, left column in
Table 3). The sensitivity analysis yielded qualitatively
similar results that did not reach statistical significance.
HCE differences were smaller among persons without
pre-exposure but nominally also indicating smaller HCE
in compliant persons in the second median half of the
HCE distribution.
Cost trajectories
The cost trajectory analysis was used to group patients
into distinct classes, based on longitudinal HCE patterns
over a one-year period after the end of the assessment
phase (Fig. 4). The k-means based algorithm identified
four robust groups, which were reflected both in the full
and the previously unexposed groups. Parametrizations
with fewer or more groups were inferior with respect to
percent correctly classified and residual sums of squares
(supplementary Figure 1).
In Fig. 4, the y-axis reflects average monthly HCE, the
x-axis illustrates months since start of the outcome ob-
servation period. The analyses of the full and unexposed
Fig. 3 Health care expenditure differences between compliers and non-compliers across the full health care expenditure distribution. The
decomposition analysis took the following potential confounders into account: age, sex, living in a French-speaking or Italian-speaking canton,
degree of urbanity of place of living, having a high deductible, participating in a managed care model, having at least one supplementary
insurance, having had an inpatient stay in the screening period (other than the index hospitalization for myocardial infarction), having had high
medication expenditures of at least CHF 5000 in the screening period, number of pharmaceutical cost groups (which are drug-prescription based
indicators for co-morbidities). Percentiles represent the 9 points in the HCE distribution that split the full sample into 10 equally large
parts (deciles)
von Wyl et al. BMC Health Services Research         (2020) 20:1125 Page 8 of 13
Table 3 Distributional cost composition analysis
Deciles HCE 4-class combination
(main analysis)
3- & 4-class combination
(sensitivity analysis)
Full population (n = 1840)
1 55 − 303 [− 659; 53] −220 [− 732; 292]
2 1837 −90 [− 473; 293] 107 [− 397; 611]
3 2898 162 [− 345; 669] 379 [− 229; 988]
4 4386 510 [−164; 1184] 693 [− 106; 1493]
5 6779 995 [33; 1958] 982 [− 98; 2062]
6 10,062 1730 [268; 3192] 1304 [− 194; 2801]
7 15,135 2504 [357; 4652] 1475 [− 674; 3624]
8 23,369 3516 [182; 6850] 2291 [− 1341; 5923]
9 42,046 4984 [− 1360; 11,328] 6987 [− 823; 14,798]
Not pre-exposed (n = 542)
1 629 − 340 [− 1074; 395] − 1082 [− 5818; 3654]
2 1400 − 332 [− 836; 172] − 479 [− 1779; 821]
3 1979 −315 [− 933; 303] −72 [− 1250; 1105]
4 2544 − 132 [− 1007; 743] 328 [− 1258; 1914]
5 3455 202 [− 1124; 1529] 857 [− 1388; 3101]
6 4879 587 [− 1548; 2722] 1277 [− 2013; 4567]
7 7949 1200 [− 1968; 4367] 1716 [− 3359; 6792]
8 12,058 2087 [− 2436; 6610] 3881 [− 4434; 12,196]
9 21,928 4317 [− 2969; 11,603] 4233 [− 21,459; 29,924]
This table illustrates results from the counterfactual distribution analysis (total costs and costs attributed to compliance). Numbers in [square brackets] represent
bootstrap-based 95% confidence intervals. HCE amounts represent Swiss francs (CHF). The decomposition analysis took the following potential confounders into
account age, sex, living in a French-speaking or Italian-speaking canton, degree of urbanity of place of living, having a high deductible, participating in a
managed care model, having at least one supplementary insurance, having had high medication expenditures of at least CHF 5′000 within 360 days before the
index date, having had an inpatient hospital stay within 360 days before the index date, number of pharmaceutical cost groups (which are drug-prescription
based indicators for co-morbidities). Deciles represent the 9 points in the HCE distribution that split the full sample into 10 equally large parts
Positive values indicate lower health care expenditures (HCE) in compliers, and vice versa
Fig. 4 Cost trajectories. Numbers in figure legend indicate: trajectory group number, proportion of the analyzed sample, average total health care
expenditures over full 12-month period (standard deviation)
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samples each suggested the presence of one large group
(n = 1302, 78% and n = 429, 83%) with comparatively low
average costs of CHF 6245 (full sample) and CHF 3851
(unexposed group) annually. The second largest groups
comprised n = 245, 15% and n = 62, 12% of persons in
the respective samples, but with substantially higher an-
nual HCE of CHF 26,504 and CHF 19,584 and occa-
sional peaks. The HCE spikes observed in group 2 (as
well as in the high-cost groups 3 and 4) were largely
driven by inpatient hospitalization costs (supplementary
Figures 2 & 3), which constituted a high fraction of all
HCE in all groups but the low-cost group 1.
On the basis of these findings, we evaluated our hy-
pothesis that taking 4-class combination treatment (resp.
3- or 4-class therapies in the sensitivity analysis) as
recommended may be linked to a higher probability of
belonging to the more favorable low-cost group 1. The
main analysis (Table 4) of the full population provided
evidence for the hypothesis, as suggested by the overall
p-value below the specified threshold of 0.05 and de-
creasing relative risk ratios below 1 (0.89, 0.71, and 0.20
for trajectory groups 2 to 4 when using the low cost
group as reference, respectively). The latter indicates
that, after controlling for important confounders, indi-
viduals taking 4-class combinations have a decreasing
probability of belonging to one of the high-cost groups.
Repeating the analysis for the sample of previously
unexposed individuals, as well as when applying the sen-
sitivity analysis definition of compliance, yielded incon-
clusive results however, mostly because numbers in
high-cost trajectory groups were quite small.
Summary Table 5 illustrates the conclusions from the
individual analyses. Recommended 4-class MI preven-
tion was associated with robust HCE reductions in the
full analysis sample, whilst compliance benefits among
persons without prior exposure to MI prevention drugs
were less clear, also due to a lack of statistical power.
Discussion
Using reimbursement claims data from 1840 Swiss
insurees, this analysis attempted to dissect economic
consequences of non-compliance with pharmacological
secondary prevention after a myocardial infarction.
Using different methods to mitigate the healthy adherer
bias and to explore effects of compliance across the full
HCE distribution, we observed robust benefits of com-
pliance for patients receiving 4-class combination treat-
ment. As shown in Table 5, compliance with 4-class
combination treatment was generally associated with
statistically significant reductions and more favorable
cost trajectory outcomes when analyzing all insurees.
Moreover, compliance also went along with a markedly
decreased risk for death during the observation period
(that is, up to 390 days after index hospitalization dis-
charge), but not for hospital readmission.
However, our sample included over 70% persons who
likely had already experienced cardiovascular health
problems prior to the index hospitalization and were
pre-exposed to drugs for MI prevention. Therefore, we
also performed sub-analyses on persons without pre-
exposure, thereby assuming that the index hospitalization
reflected the first myocardial infarction event. Al-
though conclusions remained qualitatively the same
(except in the trajectory analysis), the results no lon-
ger reached statistical significance, potentially due to
the smaller sample size.
Overall, the findings fall well in line with previous re-
search in the same field suggesting health benefits [9,
27] and lower health care expenditures for persons with
a myocardial infarction who comply with secondary pre-
vention recommendations [3, 11, 12, 28]. Although con-
ducted in a Swiss setting, the findings are likely
transferrable to target populations with similar demo-
graphics in other social health insurance schemes (e.g.
Germany or the Netherlands).
Table 4 Comparison of cost trajectory groups











1 478/1302 (36.7) Ref. 0.0191 192/429 (44.8) Ref. 0.5253
2 71/245 (29.0) 0.89 [0.65; 1.22] 25/62 (40.3) 0.84 [0.47; 1.50]
3 22/87 (25.3) 0.71 [0.42; 1.21] 8/14 (57.1) 2.29 [0.67; 7.88]
4 3/31 (9.7) 0.20 [0.06; 0.71] 5/12 (41.7) 0.81 [0.24; 2.77]
3- & 4-class combinations
(sensitivity analysis)
1 353/1302 (27.1) Ref. 0.5457 134/429 (31.2) Ref. 0.4777
2 65/245 (26.5) 1.07 [0.77; 1.48] 20/62 (32.3) 1.19 [0.65; 2.16]
3 28/87 (32.2) 1.44 [0.88; 2.34] 2/14 (14.3) 0.38 [0.07; 1.95]
4 7/31 (22.6) 0.96 [0.40; 2.34] 4/12 (33.3) 1.24 [0.34; 4.46]
Distribution of compliers and non-compliers across the four trajectory groups (Fig. 4). This analysis investigates whether persons complying with a specific
prevention drug combination have a higher probability of being included in the most favorable cost trajectory 1 (used as a reference). A multinomial logistic
regression was used to test this hypothesis. The model was estimated for compliance status to a specific drug (main variable of interest shown in the table) and
confounder adjustments as described in the methods section (coefficients not shown). P-values < 0.05 are highlighted in bold
Abbreviations: RRR multivariable Relative Risk Ratios, 95% CI 95% Confidence Intervals, Traj Trajectory
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From a methodological standpoint, the application of
novel analytic approaches highlighted two important
issues. First, the healthy adherer bias was indeed a
confounding force and needs to be dealt with adequately
in future studies. In particular, inverse probability
weighted HCE difference estimates tended to be sub-
stantially larger than unweighted estimates; much so
because a substantial number of persons died during the
observation period, which was accounted for by our for-
mulation of inverse probability weights. Of note, because
our analysis omitted cantonal cost contributions to in-
patient stay HCE, the estimates may even underestimate
the actual HCE difference between compliant and non-
compliant groups.
Moreover, the distributional analyses revealed that
HCE reductions were larger between compliers and
non-compliers as the overall level of HCE increased.
Along the same lines, compliers had - after confounder
adjustment - a greater likelihood for a more favorable
HCE trajectory over 1 year after the assessment period
than non-compliers (Table 4). These additional results
complement the analysis of HCE means based on two-
part regressions and suggest that cost benefits of compli-
ance to 4-class combination therapy may in fact be
driven by a prevention of costly complications (as indi-
cated by a lower probability for compliers to belong to a
high cost trajectory, as well as the increasing cost differ-
ence between compliers and non-compliers with rising
overall HCE). Because inpatient hospitalizations are a
major driver of HCE and hospitalizations were more
frequently observed in the non-compliant group, one
could speculate that better compliance with recom-
mended secondary MI prophylaxis may translate into
a lower risk for worsening of cardiovascular problems
(possibly requiring hospital interventions). However,
our database included limited information to substan-
tiate this hypothesis, and these aspects clearly warrant
further investigations as they may shed further light
on the mechanisms of compliance-associated cost
benefits.
The present analysis is – to our knowledge – one of
the first to demonstrate a more differentiated cost effect
of secondary MI prevention. Overall, the mix of methods
we utilized has the potential to shed further light on the
distribution and dynamics of HCE consequences of non-
compliance. These methods have similar data require-
ments as standard multivariable analyses, can be
implemented in standard software packages, and will
easily translate to other disease domains as well. Fur-
thermore, the findings have potential policy implications.
Our results suggest that better compliance with second-
ary prevention treatments for myocardial infarction may
lead to fewer health care expenditures. If further corrob-
orated, this would imply that compliance with secondary
MI prevention guidelines should be actively encouraged
and monitored.
Some limitations need to be mentioned. Because of
the observational nature of the analysis there remains a
risk for residual confounding; all the more because the
administrative database used only contains limited
Table 5 Summary of results
Summary of conclusions from Tables 2, 3 and 4. A minus (−) sign indicates no HCE reduction among compliant persons (meaning either no difference or even an
increase.). Downward arrows indicate lower HCE in compliant persons, which have reached statistical significance < 0.05 if combined with a star (*) and in red
bold. For the counterfactual decomposition analysis, the combination of symbols indicates that HCE differences become apparent only in the second median of
the HCE distribution
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clinical information. Given this residual risk of bias, the
observed cost differences between compliers and non-
compliers should still not be considered causal, although
they fall well within ranges observed by other studies.
Further limitations are the restricted outcome observa-
tion period, the unavailability of information on drug
intake by patients, as well as the static compliance defin-
ition based on a single time-point. Future analyses
should, for example, include more detailed information
on comorbidities, perform investigations into long-term
outcomes and potentially develop more refined, dynamic
measures of treatment compliance.
Conclusions
By using novel analytical methods to examine distribu-
tions and trajectories of health care expenditures this
study found that compliance with recommended sec-
ondary prevention consisting of 4-class combinations
after myocardial infarction was associated with lower
health care costs. The inclusion of methods for investi-
gating the full dynamics and distribution of health care
expenditures offers potential for more personalized cost-
benefit analyses.
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